"GOOD CAUSES" CROWDFUNDING AS A DRIVER FOR BEHAVIOURAL CHANGE IN DEMAND RESPONSE SCENARIOS

International audienceThe purpose of the CITYOPT Nice pilot project is to reduce domestic consumption during peak load hours, by engaging residents with demand response scenarios through a mobile app. This paper analyses the CITYOPT approach, suggesting that, when economic rewards are missing, a mix of educational activities, community involvement, social proof, and altruistic rewards could be a significant motivation for potential users. This study also explores possible positive consequences of crowdfunding campaigns to motivate participation and long-term engagement. Moreover, 8 other areas of improvement that could lead to higher user engagement were elicited during the research. Results imply that behaviour change considerably contributed to reducing the average energy consumption during the peak loads, and suggest that there is space for replication of the CITYOPT French pilot in other countries

Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey

OBJECTIVE: To determine whether exposure to angiotensin-converting enzyme (ACE) inhibitors prior to the onset of scleroderma renal crisis (SRC) leads to worse outcomes of SRC. METHODS: Prospective cohort study of incident SRC subjects. The exposure of interest was ACE inhibitors prior to the onset of SRC. The outcomes of interest were death or dialysis during the first year after the onset of SRC. RESULTS: A total of 87 subjects with incident SRC were identified and 1-year follow-up data were obtained in 75 (86%) subjects. Overall, 27 (36%) subjects died within the first year and an additional 19 (25%) remained on dialysis 1 year after the onset of SRC. In adjusted analyses, exposure to ACE inhibitors prior to the onset of SRC was associated with an increased risk of death (hazard ratio 2.42, 95% CI 1.02, 5.75, p < 0.05 in the primary analysis and 2.17, 95% CI 0.88, 5.33, p = 0.09 after post-hoc adjustment for pre-existing hypertension). CONCLUSION: Overall, the 1-year outcomes of SRC were poor. Prior exposure to ACE inhibitors was associated with an increased risk of death after the onset of SRC, although there was uncertainty around the magnitude of the risk and the possibility of residual confounding could not be ruled out. Further studies will be needed to confirm these findings

Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis: results from the International Scleroderma Renal Crisis Survey

L

Glycosinolates et angiogenèse tumorale

International audienc

D5. Rapport Final du projet Ecofamilies

36 pages, Pacalabs Ecofamiliesno abstrac

ECOFAMILIES project - Summary and main outcomes

Emilie Thibault (editor),CSTB-EKENOS-I3M-ICT Usage Lab, Pacalabs Ecofamiliesno abstrac

Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects

<div><p></p><p><i>Objective</i>: Autoantibodies directed against the two principal antigens of the human exosome complex, PM75 and PM100, are present in systemic sclerosis (SSc) sera and have been associated with myositis and calcinosis. However, there is a paucity of data on the clinical correlates of these autoantibodies separately and in the absence of other SSc-specific antibodies. The aim of this study was to assess the clinical correlates of monospecific anti-PM75 and anti-PM100 in SSc. <i>Methods</i>: A tri-nation cohort of 1574 SSc subjects was formed, clinical variables were harmonized and sera were tested for anti-PM75 and anti-PM100 antibodies using a line immunoassay. <i>Results</i>: Forty-eight (3.0%) subjects had antibodies against PM75 and 18 (1.1%) against PM100. However, only 16 (1%) had monospecific anti-PM75 antibodies and 11 (0.7%) monospecific anti-PM100 antibodies (i.e. in isolation of each other and other SSc-specific antibodies). Monospecific profiles of each autoantibody included more calcinosis. An increased frequency of myositis was only seen in subjects positive for both anti-PM75 and anti-PM100 antibodies. Lung disease was only associated with anti-PM75 and subjects with anti-PM100 antibodies had better survival compared to other antibody subsets. <i>Conclusion</i>: The prevalence of monospecific anti-PM75 and anti-PM100 antibodies in this large SSc cohort was low. Disease features associated with anti-PM/Scl antibodies may depend on particular and possibly multiple antigen specificities. However, due to the small samples, these results need to be interpreted with caution. International collaborations are key to understanding the clinical correlates of uncommon serological profiles in SSc.</p></div